Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic appointed Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning June 1, 2026. Lundgren succeeds Daniel Vitt, who will remain on the board and oversee scientific strategy. Lundgren brings nearly two decades of biopharma experience, including a key role in launching Ocrevus at Genentech/Roche. He will lead Immunic through the pivotal Phase 3 ENSURE trial readout for vidofludimus calcium in relapsing multiple sclerosis, expected by year-end 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.